ArticleFrontiers in genetics2026
Transcriptional signatures of respiratory syncytial virus (RSV) infection using relaxed magnitude altitude score with hub-centric network analysis (RMAS-HCNA).
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Respiratory syncytial virus A (RSVA) and respiratory syncytial virus B (RSVB) may induce distinct airway host responses. We compared them with influenza A virus (IAV) and human metapneumovirus (hMPV) in airway organ tissue equivalents (OTEs) and developed the Relaxed Magnitude Altitude Score with Hub-Centric Network Analysis framework (RMAS-HCNA). Methods: OTEs were infected with RSVA-GFP5 or RSVB-GFP3 at low multiplicity of infection and profiled at 24 and 72 h using the NanoString nCounter Host Response Panel. Previous IAV and hMPV profiles were integrated. Analyses included source-matched differential expression, cross-virus ranking, network-based module selection, nested cross-validation, and Gene Ontology Biological Process enrichment. Results: RSVA showed the strongest temporal expansion and developed a late response centered on intracellular transport, localization, and organelle organization. RSVB remained the most restricted response, shifting from early inflammatory and signaling-associated activity to a later interferon-stimulated profile. IAV maintained a broad antiviral response, whereas hMPV combined limited induction with extensive late downregulation of stress, catabolic, metabolic, and transport-related processes. A shared antiviral component was present across infections, while downregulated responses were largely virus dependent. Under five-fold outer and four-fold inner nested cross-validation, the selected genes achieved a mean outer-test Macro F1 of 0.859 and balanced accuracy of 0.888, compared with 0.604 and 0.616 for the all-gene comparator. Discussion: The four viruses shared an antiviral foundation but followed distinct temporal and functional trajectories. The framework identified compact, biologically representative panels that generalized better than the complete measured gene set, although independent genome-wide and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.